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Introduction
Natural products play a predominant role in the 
development of new therapeutic agents (Newman 
and Cragg 2016). Actinobacteria represent the most 
prominent group of microorganisms, which produce 
bioactive compounds. They synthesize approximately 
two-thirds of all naturally derived antibiotics currently 
used in medicine, veterinary practice and agriculture. 
Majority of these molecules originate from Streptomyces 
genus (Barka et al. 2016; Chater 2016). 
A traditional approach in obtaining novel bioactive 
agents, especially with unique chemical structures and 
biological significance, relies on distinct microorgan-
isms isolated from different, often secluded, environ-
ments. Actinobacterial strains commonly derive from 
soil (Guo et al. 2015), but they are also abundantly 
present in seas and oceans (Hassan et al. 2015; Xu 
et al. 2017). Moreover, extreme habitats such as caves 
(Jiang et al. 2015), deserts (Goodfellow et al. 2017) or 
Antarctic ecosystems (Lee et al. 2012) are recognized 
as valuable sources of actinomycetes producing novel 
metabolites of pharmacological importance (Solecka 
et al. 2013; Singh et al. 2018). Biosynthesis of second-
ary metabolites depends on the growth conditions of 
each strain. For years researchers have been applying 
different modifications in nutrients and physicochemi-
cal factors during fermentation processes to optimize 
the production of bioactive compounds (Rajnisz et al. 
2016). Currently, modeling and analysis of fermentation 
processes is performed by the statistical optimization 
approach, e.g. response surface methodology, which 
enables enhanced production of antibiotics, enzymes 
and probiotics (Latha et al. 2017). 
Genome sequencing can also be applied to detect the 
genes responsible for production of secondary metab-
olites besides those that were isolated under stand-
ard cultivation conditions (Thong et al. 2015). Most 
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A b s t r a c t
The growing resistance of microorganisms towards antibiotics has become a serious global problem. Therapeutics with novel chemical 
scaffolds and/or mechanisms of action are urgently needed to combat infections caused by multidrug resistant pathogens, including 
bacteria, fungi and viruses. Development of novel antimicrobial agents is still highly dependent on the discovery of new natural prod-
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most effective compounds with antibacterial activity. In turn, the highest potency among selected antifungal compounds is exhibited by 
enduspeptide B, neomaclafungins A-I and kribelloside D, while ahmpatinin iBu, antimycin A1a, and pentapeptide 4862F are recognized 
as the strongest antiviral agents.
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microbially derived natural products are produced via 
metabolic pathways encoded by adjacent chromosomal 
genes: biosynthetic gene clusters (BGCs). BGCs encode 
enzymes, regulatory proteins and transporters that are 
necessary to produce, process and export a metabolite 
(Medema and Fischbach 2015). On average, BGCs 
encompass 1.64 Mbp (16% of actinomycete coding 
capacity), encoding 35 secondary metabolites. The 
largest number of natural products was determined to 
be encoded by Kutzneria albida, S. bingchenggensis and 
S. rapamycinicus strains, which devote 2.5–3.09 Mbp 
(> 20% of coding capacity) to encode 48–53  second-
ary metabolites (Wink et al. 2017). Most of BGCs are 
cryptic or poorly expressed under laboratory condi-
tions (Baltz 2011). However, many methods have been 
developed to activate the actinobacterial secondary 
metabolism, including combined cultures and use of 
goadsporins (Onaka 2017). An effective strategy in 
the development of strains with enhanced secondary 
metabolism was established with the recent advance-
ment of whole-genome sequencing, systems biology 
and genetic engineering. In this aspect, the “-omics” 
technologies (genomics, transcriptomics, proteomics 
and metabolomics) together with bioinformatic are 
especially useful tools in inducing the overproduction 
of actinomycetes secondary metabolites. The past few 
years were an exciting time for metabolic engineering 
of actinomycetes as several novel in silico methods to 
automate the analysis of secondary metabolism in bac-
terial genomes (e.g. antibiotics & Secondary Metabo-
lite Analysis Shell, antiSMASH) had been introduced 
(Medema et al. 2011). 
In this review, we present secondary metabolites of 
Actinobacteria, which possess antibacterial, antifungal 
and antiviral activities. Their origin and chemical fea-
tures are also reported. We draw special attention to 
novel agents described from 2011 to April 2018, dis-
playing minimum inhibitory concentrations (MICs) 
less than or equal to 10 µg/ml. Additionally, we dis-
cuss on the previously described compounds that were 
recently characterized with new properties and func-
tion. The present article is a thematic continuation of 
a review published in 2012 (Solecka et al. 2012).
Antibacterial activity
Nowadays, antibiotic resistance of microorganisms 
is one of the biggest threats to global health, food secu-
rity and development. The World Health Organization 
(WHO) Global Report on the surveillance of antimi-
crobial resistance has established that bacterial resist-
ance to commonly used drugs in infection treatment 
has reached alarming levels in many parts of the world 
(WHO 2014). In 2017, WHO released its first list of 
most concerning “priority pathogens” for human health 
– a catalogue of twelve families of bacteria for which 
new antibiotics are urgently needed (WHO 2017). 
According to O’Neill’s independent review (2016) about 
700 000 people around the world die annually due to 
drug-resistant infections. If current trends continue, 
such infections could entail the death of 10  million 
people a year by 2050 (O’Neill 2016). In this context, 
the discovery of new bioactive compounds, particularly 
those with new modes of action, is not only needed 
for modern medicine but absolutely required to avoid 
future pandemics.
Below authors present the major chemical structural 
groups of newly discovered compounds with antibacte-
rial activity.
Spirotetronate compounds. Among novel mol-
ecules that were reported since 2011 is maklamicin 
(Fig. 1), a  new spirotetronate-class polyketide. It is 
a  polycyclic compound from the culture extract of 
endophytic Micromonospora sp. GMKU326 isolated 
in Thailand. Maklamicin showed potent antimicrobial 
activities against Gram-positive bacteria, including 
Micrococcus luteus, Bacillus subtilis, Bacillus cereus, 
Staphylococcus aureus, and Enterococcus faecalis with 
MIC values of 0.2, 1.7, 6.5, 13, and 13 μg/ml, respectively, 
and significantly lower activity against Candida albicans 
(MIC = 50 μg/ml). The compound displayed also mod-
erate cancer cell cytotoxicity (Igarashi et al. 2011). 
Another newly discovered spirotetronate antibiotic 
of polyketide origin is nomimicin, which was isolated 
from the culture extract of Actinomadura sp. TP-A0878. 
The molecule showed antimicrobial activities against 
M. luteus, C. albicans and Kluyveromyces fragilis with 
MIC values of 6.3, 12.5 and 12.5 μg/ml, respectively. 
Moreover, nomimicin displayed weak cytotoxicity 
against human cancer cells (Igarashi et al. 2012).
Significant antibacterial and antitumor activities 
were demonstrated by lobophorin F, a new spiro-
tetronate molecule isolated from Streptomyces sp. 
SCSIO 01127. The MIC values towards Bacillus thur­
ingiensis, S. aureus and E. faecalis equaled 2, 8, 8 µg/ml, 
respectively (Niu et al. 2011). Interesting bioactivities 
were demonstrated by secondary metabolites of Strepto­
myces sp. strain MS1 00061 originating from the South 
China Sea. The three detected secondary metabolites 
belong to the lobophorin family, and one of them, lobo-
phorin G, was described for the first time. The others, 
lobophorin A and B, were previously known as anti-
inflammatory agents. Together, these three metabolites 
exhibited a significant anti-BCG (anti-Mycobacterium 
bovis) effect. Furthermore, they exhibited moderate 
anti-tuberculosis (anti-Mycobacterium tuberculosis) 
properties and diverse activity towards B. subtilis (Chen 
et al. 2013). Another, novel lobophorin H inhibited the 
growth of M. tuberculosis, B. subtilis and S. aureus and 
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was toxic towards the human CEM-TART cell line (Pan 
et al. 2013; Lin et al. 2014). 
Ansamycin-type compounds. Four new ansamycin-
type (aromatic moiety bridged by an aliphatic chain) pol-
yketides, named chaxamycins A-D were isolated from 
the Streptomyces sp. strain C34 from the Chilean hyper-
arid Atacama Desert soil. Antibacterial activity assays 
showed chaxamycin D (Fig. 1) to present the strong-
est activity against S. aureus ATCC 25923 and Escheri­
chia coli ATCC 25922 (MIC = 0.05 and 1.21 μg/ml, 
respectively) as well as against a panel of methicillin-
resistant S. aureus (MRSA) clinical isolates with MICs 
ranging from 0.06–0.25 μg/ml (Rateb et al. 2011a). The 
other chaxamycins (A-C) exhibited also the ability to 
inhibit the intrinsic ATPase activity of the heat shock 
protein 90 (Hsp) (41–46% of inhibition at 100 µM).
β-diketones, aromatic ketones. Three new bioactive 
β-diketones were discovered from the culture broth of 
S. asenjonii KNN 42.f isolated from an extreme hyper-
arid Atacama Desert soil in Northern Chile. In addition 
to thirteen already known substances, three novel com-
pounds – asenjonamides A, B and C, were also purified. 
Fig. 1. Chemical structures of compounds with antibacterial activities.
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These new active metabolites were grouped in the β-dike- 
tone family of polyketides. The highest antibacterial activ- 
ity was determined for asenjonamide C, which exhibited 
MIC = 1.8 µg/ml against methicilin-sensitive S. aureus 
(MSSA), MIC = 3.9 µg/ml against E. faecium and 
MIC = 5.4 µg/ml against E. coli (Abdelkader et al. 2018).
Moreover, significant antimicrobial properties 
against S. aureus, B. subtilis, E. coli and C. albicans (MICs 
between 0.25–2.5 μg/ml) were determined for a new 
polyketide glycoside, gilvocarcin HE (Fig. 1), obtained 
from the ethyl acetate extract of Streptomyces sp. 
QD01-2 (isolate from soil sample collected at Huiquan 
Square in China). The compound showed also mod-
erate cytotoxicity against the MCF-7, K562 and P388 
cell lines, with IC50 values of 36, 39 and 45 µM, respec-
tively. Results prove that the vinyl side chain helps to 
increase the cytotoxicity and antimicrobial activities 
of gilvocarcin-type glycosides (Hou et al. 2012).
Two new chloroanthrabenzoxocinones antibiotics 
– zunyimycins B and C – were isolated from the Strepto­
myces sp. FJS31-2 fermentation broth. The strain was 
isolated from a soil sample from the Fanjing Mountain of 
Guizhou Province, China. Zunyimycin C presents good 
antimicrobial activity toward S. aureus ATCC 29213 
(MIC = 0.94 µg/ml) and five clinical MRSA isolates 
(MICs between 3.75–8.14 µg/ml) (Lü et al. 2017).
Tetracenediones. Novel polyketides named formi-
camycins A-L were discovered as secondary metabolite 
products of the S. formicae KY5 strain isolated from 
Kenyan ants Tetraponera penzigi. Formicamycin  J 
(Fig. 1) was shown to inhibit the growth of the clinically 
relevant pathogens – MRSA and vancomycin-resistant 
Enterococcus faecium (VRE) with MICs of 0.41 and 
0.82 µg/ml, respectively. Other tested formicamycins 
were less potent (Qin et al. 2017).
Lactones. Application of the “one strain-many com-
pounds” approach on the Streptomyces strain using 
a range of cultivation media resulted in the isolation 
and identification of several new compounds. These 
included three new chaxalactins A-C from the rare 
class of macrolactone polyketides detected together 
with already known deferroxamine E, hygromycin A, 
and 5”-dihydrohygromycin A. Novel molecules showed 
strong activity against Gram-positive bacteria, such as 
S. aureus, L. monocytogenes, B. subtilis (MICs rang-
ing from 0.2 to 6.3 μg/ml) and weaker activity against 
Gram-negative strains like V. parahemolyticus with MIC 
of 12.5 μg/ml for chaxalactins A and C and 20 μg/ml for 
chaxalactin B (Rateb et al. 2011b). 
In 2013, Jang and colleagues described a new, prom-
ising natural product especially effective towards Bacil­
lus anthracis (MIC = 0.03 µg/ml). The compound was 
designated as anthracimycin and was shown to display 
antibacterial activity also against E. faecalis, S. pneumo­
niae, H. influenzae, Moraxella catarrhalis, MSSA, MRSA 
and vancomycin-resistant S. aureus with MICs rang-
ing from 0.03 to 4 µg/ml. Anthracimycin was isolated 
from the Streptomyces sp. strain CNH365 collected 
from marine sediments near Santa Barbara, Califor-
nia, USA. The compound was classified as a polyke-
tide antibiotic and possesses a 14-membered lactone 
ring and a chemical structure similar to that observed 
for the macrolide chlorotonil. The mode of action of 
anthracimycin is based on the inhibition of DNA/RNA 
synthesis (Jang et al. 2013). Additionally, in vivo experi-
ments revealed that anthracimycin was able to protect 
mice from MRSA-induced mortality in a murine peri-
tonitis model of infection (Hensler et al. 2014). 
An actinomycete strain isolated from marine sedi-
ment from Chuuk, Federated States of Micronesia, 
was discovered to produce two new macrolactins – A1 
(Fig. 1) and B1 (polyene cyclic macrolactones), and 
the previously known lauramide diethanolamine. All 
of them significantly inhibited the growth of Gram-
positive (B. subtilis, S. aureus) and Gram-negative 
(E. coli, P. aeruginosa) bacteria with MICs ranging 
between 0.015 and 0.125 μg/ml. Furthermore, they 
also displayed potent anti-yeast effects (MIC towards 
S. cerevisiae – 0.125 μg/ml). Unfortunately, activities of 
these compounds were weaker compared to azithro-
mycin and amphotericin B, which served as positive 
controls in the trials (Mondol and Shin 2014). 
Cruz et al. described the first hyperchlorinated angu-
cyclinones produced by Actinoallomurus sp. ID145698. 
Due to their unique structural features and wide dis-
tribution among Actinoallomurus, authors have des-
ignated these angucyclinones as allocyclinones. These 
compounds are characterized by an unusual lactone ring 
and present up to four halogens per molecule, with one 
congener representing the first natural product con-
taining a trichloromethyl substitution on an aromatic 
system. The antibacterial activity of four isolated allo-
cyclinones was determined to increase with the number 
of chlorine substituents on the methyl group. Allocy-
clinone A has three additional chlorine atoms at carbon 
C-13. This compound showed the highest antibacterial 
activity. The MICs were in the range of 0.25–0.5 μg/ml 
against S. aureus, S. pyogenes and E. faecalis, except for 
E. faecium (MIC = 4 μg/ml). As expected, none of the 
evaluated, clinically relevant resistance mechanisms 
affected the activity of the compounds (Cruz et al. 2017). 
The first-time reported compound RSP 01 (Fig. 1) is 
a bicyclic chromopeptide lactone from the actinomycin 
group. It was found to be biosynthesized together with 
the already described RSP02 by Streptomyces sp. RAB12 
isolated from soil samples collected from the garden 
near the CSIR-Indian Institute of Chemical Technol-
ogy, Hyderabad, India. Both RSP 01 and 02 revealed 
a chemical structure similar to actinomycin D. How-
ever, RSP 01 has a ketocarbonyl group at the fourth car-
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bon of the proline moiety, which is absent in actinomy-
cin D. Results of bioactivity assays suggest that RSP 01 
has a higher antimicrobial potential in comparison with 
actinomycin  D. The MICs values for RSP  01 ranged 
from 0.007 to 0.06 µg/ml against S. aureus, P. aerugi­
nosa, S. typhi and B. subtilis (Rathod et al. 2018). 
Macrolides are also recognized as lactones. They 
belong to a class of natural products that consists of 
a  macrocyclic lactone ring (14-membered or more) 
to which one or more deoxy sugar moiety can be 
attached. Two 16-membered macrolides, tylosin ana-
logues, were obtained from a wbIA disruption mutant 
of Streptomyces ansochromogenes (wbIA, an Actino-
bacteria-specific gene controlling major developmen-
tal transition). These novel natural products exhibited 
moderate activity against Gram-positive bacteria, such 
as: Streptococcus pyogenes, Streptococcus pneumoniae, 
B. subtilis, B. cereus and S. aureus with MIC values in the 
range of 3.53–58.5 µg/ml. It is noteworthy that tylosin 
derivatives showed stronger bactericidal effects towards 
S. pneumoniae than tylosin itself (Lu et al. 2015).
A novel 48-membered polyol macrolide, named 
quadoctomycin, was isolated from Streptomyces sp. 
MM168-141F8. It showed potent antibacterial activity 
against S. aureus. The MIC values were evaluated for 
three MSSA, five MRSA and six E. faecalis strains and 
ranged between 1–2 µg/ml. In turn, quadoctomycin did 
not show antimicrobial activity toward Gram-negative 
bacteria (Sawa et al. 2018).
In 2017, Khalil et al. reported on the identification 
of amycolatopsins A, B and C, the representatives of 
a rare family of glycosylated polyketide macrolides that 
are related to the apoptolidin, and novel metabolites of 
ammocidin structure class derived from the southern 
Australian soil isolate, Amycolatopsis sp. MST-108494. 
Only amycolatopsins A and C were active towards 
M. bovis and M. tuberculosis, reaching IC50 values of 
0.5–7.0 μg/ml. In turn, all three compounds showed 
cytotoxicity against mammalian NCIH-460 and SW620 
cells (Khalil et al. 2017). 
Lactams. Streptomyces zhaozhouensis CA-185989 
from marine sediment collected near Utonde, Equa-
torial Guinea was found to produce new bioactive 
secondary metabolites from the class of polycyclic 
tetramic acid macrolactams, isoikarugamycin (Fig. 1) 
and 28-N-methylikarugamycin. These novel com-
pounds demonstrated potent antibacterial and anti-
fungal activities and were shown to be active towards 
S. aureus, C. albicans and A. fumigatus presenting MICs 
between 1 and 8 µg/ml (Lacret et al. 2014). 
Quinones. Heterologous expression of specific 
gene clusters (corresponding to two eDNA-derived 
KSβ sequence tags) in Streptomyces albus enabled the 
isolation of new polyketides, arenimycins C (Fig. 1) 
and D with potent antibacterial activities. Arenimy-
cins C and D belong to benzo[α]naphthacene quinones 
and were shown to be active towards MRSA USA300 
(MIC = 0.098 and 0.19 μg/ml, respectively) and B. subti­
lis RM125 (MIC = 0.0015 and 0.39 μg/ml, respectively) 
(Kang and Brady 2014).
Identification of pseudonocardians A-C, new dia-
zaanthraquinone analogs, substantiated the potential 
of marine actinomycetes as a source of novel drugs. 
These two compounds derived from Pseudonocardia sp. 
SCSIO 01299 collected from the deep-sea sediment of 
the South China Sea. The activity profile revealed that 
pseudonocardians A and B were notably potent against 
bacterial strains as well as tumor cell lines. The MIC 
values towards S. aureus, E. faecalis and B. thuringensis 
ranged between 2–4 µg/ml (Li et al. 2011).
Another group of quinones – pyranonaphtho-
quinone antibiotics, known as selective inhibitors of 
the serine-threonine kinase AKT (protein kinase B), 
has been enlarged in 2015 to include a new member 
– xiakemycin A. The compound was isolated from the 
culture broth of Streptomyces sp. CC8-201 originat-
ing from the soil of a Chinese karst cave. In a panel of 
antibacterial and antiproliferative assays, xiakemycin A 
demonstrated activity towards Gram-positive bacteria 
(S. aureus, S. epidermidis, E. faecalis and E. faecium) with 
MICs ranging from 2 to 16 μg/ml (Jiang et al. 2015).
In 2013, Song et al. reported the isolation of four 
new sesquiterpenoid naphthoquinones, marfuraquin-
ocins A-D, from the fermentation broth of Streptomyces 
niveus SCSIO 3406 (South China Sea, sediment sample). 
All compounds were evaluated for their potential anti-
bacterial and cytotoxic properties. Marfuraquinocins 
A, C and D were active towards S. aureus ATCC 29213 
with equivalent MICs of 8 μg/ml. Additionally, mar-
furaquinocins C and D exhibited antibacterial activity 
against the methicillin-resistant S. epidermidis clinical 
isolate shhs-E1 with the same MIC values (8 μg/ml) 
(Song et  al. 2013). 
Xin and colleagues discovered also other quinone 
derivatives with antibacterial and antitumor properties 
that is produced by actinomycetes as secondary meta-
bolites. Among them were new modified anthraqui-
nones – fradimycins A and B (capoamycin-type agents) 
isolated from marine Streptomyces fradiae PTZ0025. 
These two substances were active against S. aureus with 
MICs of 6 and 2 µg/ml, respectively. Moreover, these 
compounds displayed cytotoxicity towards human can-
cer cell lines (Xin et al. 2012). 
Quinolones. Interesting bioactivity was observed 
for a newly recognized chlorinated quinolone of actin-
omycetes origin (Streptomyces sp. SBT345) obtained 
from the Mediterranean sponge, Agelas oroides. This 
novel natural product designated as ageloline A (Fig. 1), 
showed antichlamydial and antioxidant effects. Agelo-
line inhibited the growth of Chlamydia trachomatis 
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inclusion with IC50 value of 2.1 µg/ml. Moreover, the 
compound was shown not only to reduce oxidative 
stress, but also to decrease genomic damage induced 
by the 4-nitroquinoline-1-oxide, an oxidative stress 
inducer (Cheng et al. 2016).
Xanthones. Another promising substance with anti-
microbial potential is buanmycin, a new pentacyclic 
xanthone isolated from the culture of a marine Strep­
tomyces strain from a tidal mudflat in Buan (Republic 
of Korea). Buanmycin was shown not only to display 
strong inhibitory activity against both Gram-positive 
(S. aureus, B. subtilis, K. rhizophila) and Gram-neg-
ative bacteria (Salmonella enterica, P. hauseri) with 
MICs 0.42–12.5 μg/ml, but also to inhibit the S. aureus 
sortase A, an enzyme that plays key role in adhesion 
and host invasion by Gram-positive bacteria (with IC50 
value of 43.2 μM in comparison to IC50 = 104.4 μM for 
the p-hydroxymercuribenzoic acid, the positive con-
trol compound). Additionally, buanmycin exhibited 
potent cytotoxicity with submicromolar IC50 values as 
well as moderate antifungal activity towards C. albicans 
(MIC = 12.5 μg/ml) (Moon et al. 2014). Four novel xan-
thones (citreamicin θ A (Fig. 2), citreamicin θ B, citrea-
glycon A and dehydrocitreaglycon) were obtained by 
Liu et al. from a marine Streptomyces caelestis strain. 
All these compounds demonstrated potent activity 
towards S. haemolyticus, S. aureus and B. subtilis with 
MIC values in the range of 0.25–16 µg/ml. However, 
citreamicin  θ  A and citreamicin  θ  B were definitely 
more active than the other metabolites, probably 
due to the five-member nitrogen heterocycle in their 
structures. Additionally, they also showed cytotoxicity 
against HeLa cells (Liu, Xu et al. 2012).
Aminocoumarins. The combined approach of 
phylogenetic and chemical analyses of the Strepto­
myces community from marine sediments of British 
Columbia in Canada allowed discovering a range of 
structurally diverse actinomycetes secondary metabo-
lites. Four of them were determined as new novo-
biocin analogues. Two of them, desmethylnovobiocin 
and 5-hydroxynovobiocin (Fig. 2) were active against 
MRSA ATCC 33591 with MIC values of 16 and 8 µg/ml, 
respectively. Novobiocin is known to target the bacte-
rial gyrase by inhibiting ATP hydrolysis (Maxwell and 
Lawson 2003). Structure-activity relationships (SAR) 
studies demonstrated that analogues bearing different 
substituents at 3”-carbamoyl and 4”-OMe noviose moi-
eties, or a 5-H hydroxybenzoate ring exhibited a dra-
matic decrease or complete elimination of inhibitory 
activity against MRSA (Dalisay et al. 2013). 
Terpenoids. Three new meroterpenoids – napy-
radiomycins, together with six already known ana-
logues were isolated as secondary metabolites of the 
Streptomyces sp. strain SCSIO 10428 derived from the 
Xieyang Island (Beihai, Guangxi province, China). 
Among them were 4-dehydro-4a-dechloronapyradi-
omycin A1, 3-dechloro-3-bromonapyradiomycin  A1 
and 3-chloro-6, 8-dihydroxy-8-α-lapachone, of which 
the second compound displayed the widest bioactivity 
range. Antibacterial assays revealed that 3-dechloro-
3-bromonapyradiomycin A1 is active towards S. aureus, 
B. subtilis and B. thuringensis with MIC values at the level 
of 0.5–1 µg/ml. The compound showed also cytotoxicity 
against four human cancer cell lines (Wu et al. 2013).
A new secondary metabolite, actinomadurol (Fig. 2), 
was isolated from rare actinomycete strain, Actinoma­
dura KC191. The structure of the compounds revealed 
a unique 19-norditerpenoid-carbon backbone, which 
provided a novel scaffold for antibiotic discovery. 
This molecule displayed significant inhibitory activ-
ity towards various bacterial strains, such as B. subti­
lis ATCC 6633, S. aureus ATCC 6538p, K. rhizophila 
NBRC 12708, P. hauseri NBRC 3851 and S. enterica 
ATCC 14028 with MIC values of 0.39 to 3.12 μg/ml 
(Shin et al. 2016). 
Peptides. A promising scaffold for the treatment 
of Gram-positive bacterial infections is kocurin 
(PM181104) (Fig. 2), a new thiazozyl peptide obtained 
from Kocuria palustris F-276,345. This metabolite dis-
plays much lower MICs (0.008–0.512 µg/ml) towards 
B. subtilis and drug-resistant strains of S. aureus, E. fae­
cium or E. faecalis than the standard antibiotic, line-
zolid. The most likely mode of action of this agent is 
inhibition of bacterial growth by blocking its protein 
biosynthesis at the translation stage. Furthermore, in 
vivo studies revealed that kocurin protected mice from 
organ-specific infections or even from systemic infec-
tions (Mahajan et al. 2013).
Pargamicins B, C and D are new cyclic peptide 
metabolites, which were isolated from the fermenta-
tion broth of a soil actinomycete strain, Amycolatopsis 
sp. ML1-hF4. The structure of pargamicin A was deter-
mined in 2008. Pargamicins are structurally unique 
cyclic peptides consisting of N-methyl-3-hydroxy valine, 
4-hydroxy piperazic acid (4-OH-Pip), sarcosine, pheny-
lalanine, N-hydroxy isoleucine (NOH-Ile) and pipera-
zic acid (Pip). The only structural difference between 
pargamicins is in the Pip(NOH-Ile) moiety. However, 
despite this structural similarity, antimicrobial activi-
ties of pargamicins showed remarkable differences. Par-
gamicins A and C exhibited potent antibacterial activity 
against Gram-positive bacteria, including MRSA and 
VRE. The MIC values of pargamicin C towards MSSA 
and MRSA were in the range between 2 and 4 µg/ml, 
while towards E. faecium and E. faecalis – in the range 
from 0.5 to 1 µg/ml. In turn, the antibacterial activity of 
pargamicin B and D against these bacteria was weaker. 
Both agents demonstrated MIC values equal 8 µg/ml 
towards E. faecium and E. faecalis. When assayed against 
MSSA and MRSA strains it revealed MICs in the range 
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of 8–16 and 32–64 µg/ml for pargamicin B and D, 
respectively (Hashizume et al. 2017).
Depsipeptides. Investigations of microorganisms 
from unique environments, such as the sand beach 
on Jeju, a volcanic island in the Republic of Korea, led 
to discovery of ohmyungsamycins A and B produced 
by Streptomyces sp. These new cyclic depsipeptides 
bear unusual amino acid units (N-methyl-4-metho-
xytrytophan, β-hydroxyphenylalanine, and N,N-di-
me thylvaline). The two molecules displayed various 
inhibitory activities against both Gram-positive and 
Gram-negative bacteria, including B. subtilis, Kocuria 
rhizophila and Proteus hauseri (MICs = 1.56–49.5 µg/ml). 
Ohmyungsamycin A is much more potent than ohm-
yungsamycin B with regard to its cytotoxicity and anti-
bacterial properties (Um et al. 2013). 
Fig. 2. Chemical structures of compounds with antibacterial activities.
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In 2014, a new bicyclic depsipeptide, salinamide F 
(Fig. 2), isolated from marine-derived Streptomyces 
sp. CNB-091, was described. The activity profile of 
salinamide F revealed that it is active towards E. coli 
D21f2tolC, Haemophilus influenzae, E. faecalis and Neis­
seria gonorrhoeae with MIC values of 0.20, 12.5, 12.5 
and 25 μg/ml, respectively. Moreover, it showed signifi-
cant inhibition of Gram-positive and Gram-nega tive 
bacterial RNA polymerase with IC50 = 4 μM for S. aureus 
RNAP and 2 μM for E. coli RNAP (Hassan et al. 2015).
New natural products discovered by Sun and col-
leagues, named fijimycins A and C, exhibited activ-
ity against three different MRSA strains with MICs in 
the range of 4–32 µg/ml. These novel etamycin-class 
depsipeptides were identified from the fermentation 
broth of Streptomyces sp. CNS-575 strain (Nasese, Fiji) 
(Sun et al. 2011).
Lipopeptides. The use of ultra-performance liquid 
chromatography coupled with tandem quadrupole 
and time of flight high-resolution mass spectrometry 
(UPLC-Q-TOF-HRMS) led to the identification of two 
lipopeptides from Streptomyces parvus HCCB10043. 
One of them, arylomycin A6 (Fig. 2), was a  novel 
compound and showed antibacterial activity towards 
Staphylococcus epidermidis HCCB20256 with the MIC 
of 1 µg/ml (Rao et al. 2013).
Other chemical compounds. In 2011, Phillips and 
coworkers from Merck Research Laboratories, Merck 
& Co. reported on a compound named kibdelomycin 
(Fig. 2), which constituted the first structural class of 
DNA gyrase inhibitors discovered during 60  years 
of research. This secondary metabolite is a  hexacy-
clic poly ketide-peptide hybrid with a dichloropyrrole 
moiety produced by Kibdelosporangium sp. MA7385. 
The mode of action of kibdelomycin is similar to the 
coumarin antibiotic – novobiocin, as it targets two 
subunits of topoisomerase IV and DNA gyrase  A. 
This broad spectrum antibiotic shows activity against 
MRSA (MIC = 0.5 µg/ml) as well as against S. pneumo­
niae (MIC = 1 µg/ml), E. faecalis (MIC = 2 µg/ml) and 
the Gram-negative pathogen, Haemophilus influenzae 
(MIC = 2 µg/ml) (Phillips et al. 2011). The recent stud-
ies performed with clinical strains have revealed potent 
activity of kibdelomycin against Acinetobacter bau­ 
manii (MIC = 0.125 µg/ml). There was no cross-resist-
ance observed with other gyrase inhibitors in assays 
with novobiocin- and ciprofloxacin-resistant S. aureus 
strains (Singh et al. 2015).
Antifungal activity
Among the novel antifungal secondary metabolites 
produced by actinomycetes is sceliphrolactam. This 
previously unreported compound was isolated in 2011 
from Streptomyces sp. associated with the black and 
yellow mud dauber, Sceliphron caementarium, collected 
in Wisconsin (United States). The structure, which con-
sists of polyunsaturated and polyoxygenated 26-mem-
bered macrocyclic lactam is extremely sensitive to light, 
high temperatures and Lewis acids. Despite its liability, 
sceliphrolactam demonstrated potent antifungal activ-
ity against amphotericin B-resistant C. albicans with 
MIC of 4 µg/ml (Oh et al. 2011). 
Other three novel members (15-glycidylfilipin III; 
16α, 17α-epoxyfilipin V; 16β, 17β-epoxyfilipin  V) of 
the polyene macrolide class were isolated from the cul-
tures of a soil actinomycete, S. lavenduligriseus. Among 
them, only 15-glycidylfilipin III exhibited strong inhibi-
tion of mycelia growth of C. albicans with MIC value 
of 6.25 µg/ml compared to MIC = 3.13 µg/ml for the 
control, nystatin. The other compounds displayed con-
siderably weaker fungicidal effects (MIC = 200 µg/ml) 
which ruled out the hypothesis that microbial second-
ary metabolites with an epoxide function are more toxic 
or have stronger cytostatic properties than analogs 
without the epoxide function (Yang et al. 2016). 
In 2017, a Streptomyces sp. strain was isolated from 
a soil sample collected from a coal mine at a depth of 
20 cm in Nanchang, Jiangxi, People’s Republic of China. 
Six new cyclic octa depsipeptides, enduspeptides A-F, 
were produced by this strain. The most potent anti-
fungal activities against C. glabrata ATCC 90030 with 
IC50 values of 5.33, 1.72 and 8.13 µg/ml were shown by 
enduspeptides A, B (Fig. 3) and C, respectively (Chen 
et al. 2017). 
Four new Cet1p RNA 5’-triphosphatase inhibitors, 
designated kribellosides A-D (Fig. 3) were isolated as 
secondary metabolites of a rare Actinobacteria, Kri­ 
bella MI481-42F6, found in a soil sample collected 
at Nerima-ku, Tokyo, Japan. These novel alkyl glyce-
ryl ether compounds inhibited the activity of RNA 
5’-triphosphatase from Saccharomyces cerevisiae in 
vitro with IC50 of 5–8 μM and showed antifungal activ-
ity with MICs ranging from 3.12 to 100 μg/ml against 
S. cerevisiae (Igarashi et al. 2017). 
Mohangamides A and B were purified from culture 
broth of marine Streptomyces sp. SNM55 obtained from 
the Mohang mud flat collected in the Buan, Republic of 
Korea. These unique dilactone-tethered pseudodimeric 
peptides bear two unusual acyl chains and 14 amino 
acid residues. The biological activities of these novel 
compounds were primarily evaluated against C. albi­
cans isocitrate lyase (ICL), which is a key enzyme of the 
glyoxylate cycle and enables microorganisms to grow 
on acetate, ethanol, or fatty acids in host environments. 
Mohangamides A and B displayed inhibition against ICL 
with an IC50 value of 4.4 μM and 20.5 μM, respectively. 
These compounds did not show significant antifungal 
activity when fungi were fed with glucose. Interestingly, 
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mohangamide A inhibited C. albicans that was grown 
on 2% sodium acetate (Bae et al. 2015). 
Neomaclafungin A (Fig. 3) was the main metabo-
lite from the fermentation broth of Actinoalloteichus 
sp. NPS702 that was isolated from the marine sedi-
ment collected from Usa Bay, Kochi Prefecture, Japan. 
Besides neomaclafungin A, also other neomaclafungins 
(B-I) were isolated, but in lower concentrations. All 
novel compounds possess a macrolide ring similar to 
that of maclafungin, but with different moieties substi-
tuted in C-24 and C-33 position. The MIC values for 
these new neomaclafungins (A-I) against dermatophyte 
Trichophyton mentagrophytes ATCC 9533 were between 
1–3 μg/ml (Sato et al. 2012). 
Antiviral activity
The study of a marine actinomycetes strain, Strep­
tomyces kaviengensis, isolated from the coast of New 
Ireland (Papua New Guinea) enabled Raveh and co- 
workers to identify a novel metabolite with signifi-
cant antiviral activity. The compound, antimycin A1a 
(Fig. 3), was found to be an antimycin A derivative and 
shows high potency against the Western equine enceph-
alitis virus with IC50 value of less than 4 nM and selec-
tivity index of greater than 550. Analysis of its mecha-
nism of action revealed disruption of mitochondrial 
electron transport and pyrimidine biosynthesis. More-
over, the previously known antimycin A demonstrated 
Fig. 3. Chemical structures of compounds with antifungal and antiviral activities.
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a broad spectrum activity towards a wide range of RNA 
viruses, including members of the Togaviridae, Flavi­
viridae, Bunyaviridae, Picornaviridae, and Paramyxo­
viridae families (Raveh et al. 2013). 
Promising chemical skeletons with antiviral pro-
perties are displayed by xiamycins C-E, produced by 
Streptomyces sp. #HK18 from the topsoil of a Korean 
solar saltern. New compounds were elucidated as car-
bazole-bearing indolosesquiterpenoids. Among them, 
xiamycin D exhibited the strongest effect on porcine 
epidemic diarrhea virus (PEDV) with replication with 
value of EC50 equaling 0.93 μM (cytotoxicity = 56.03 μM; 
selectivity index = 60.31). Additionally, the inhibitory 
activity of xiamycin D was confirmed by quantitative 
real-time PCR after amplification of fragments of the 
genes encoding essential structural proteins (GP6 nuc-
le o capsid, GP2 spike, and GP5 membrane) for PEDV 
replication and by Western blotting of PEDV GP2 spike 
and GP6 nucleocapsid proteins (Kim et al. 2016). 
HIV-1 protease is essential in the life cycle of HIV 
and has been used as a promising target for AIDS 
therapy. Several novel potent inhibitors of this protease 
have been reported recently. In 2013, a new inhibitor 
of HIV-1 protease, 4862F (Fig. 3) was isolated from the 
culture broth of Streptomyces albosporus I03A-04862. 
It was elucidated as N,N,N­(trimethylated)-Tyr-L-Leu-
L-Val-L-Leu-(dehydrated)-His and determined to dis-
play inhibitory activity against HIV-1 protease with 
an IC50 value of 15.26 nM (Liu, Gan et al. 2012). 
Ahmpatinin iBu (Fig. 3) is a linear peptide and 
a novel pyrrolidine derivative with an unusual amino 
acid, 4-amino-3-hydroxy-5-(4-methoxyphenyl) penta-
noic acid. It was produced by Streptomyces sp. CPCC 
202950 cultured on sterile soaked rice. Ahmpa tinin iBu 
showed significant inhibitory activity against HIV-1 
protease resulting in IC50 = 1.79 nM (Chen et al. 2018). 
Functional diversity of microbial natural products 
is favorable in regards to exploring for drugs against 
the Zika virus (ZIKV). The spread of ZIKV into North 
and South America in 2013 has caused infections of 
millions of people (Saiz and Martín-Acebes 2017). In 
2015, WHO declared a public health emergency due to 
Zika (Blázquez and Saiz 2016). Lately, a great effort has 
been put to determine drug candidates directed to viral 
targets or against cellular targets (host-targeting antivi-
rals). This approach included screening of libraries with 
different compounds and repurposing drugs already 
used in clinical practice for other diseases (Bae et al. 
2015). Among them, daptomycin (IC50 = 1 µM) and 
nanchangmycin (IC50 = 0.1 µM) showed a previously 
not described anti-ZIKV activity (Barrows et al. 2016; 
Pascoalino et al. 2016; Rausch et al. 2017). Both of these 
drugs are bioactive secondary products of Streptomy­
ces spp., for which antiviral activity was unrecognized 
before. Daptomycin is a lipopeptide antibiotic used in 
the treatment of infections caused by Gram-positive 
bacteria. It was found in the culture broth of S. rose­
osporus. In turn, nanchangmycin is produced by S. nan­
changensis and was shown to have insecticidal activity 
against silkworms and antibacterial activity in vitro.
Summary
In this review we report on more than a hundred 
of natural products of cultured actinomycetes, which 
exhibit antibacterial, antifungal or antiviral activities. 
Some of these compounds, besides antimicrobial prop-
erties show also cytotoxicity towards different tumor 
cell lines. The majority of presented agents are novel 
molecules described between 2011 and April 2018. 
Only a few of them had a known structure or were 
synthesized earlier but isolated for the first time from 
natural sources within these last seven years. Moreover, 
the majority of described compounds were discovered 
using a traditional approach of screening for metabo-
lites in the actinobacterial fermentation broth. Most of 
them inhibited the growth of Gram-positive bacteria, 
which is in accordance with previous results (Butler 
et al. 2017). Over 70% of the reported metabolites were 
produced by various Streptomyces sp. strains; the other 
compounds were produced by the following Actino-
bacteria: Amycolatopsis, Pseudonocardia, Kibdelospo­
rangium, Actinoalloteichus (family Pseudonocardi-
aceae), Micromonospora (family Micromonosporaceae), 
Actinomadura, Actinoallomurus (family Thermomono-
sporaceae), Actinokineospora (family Actinosynnemata-
ceae), Kocuria (family Micrococcaceae), Actinomyces 
(family Actinomycetaceae), Kribella (family Nocardioi-
daceae) and Nocardia (family Nocardiaceae). About 
40% of the described metabolites were biosynthesized 
by species originating from marine ecosystems, about 
43% were obtained from terrestrial actinomycetes, 
while 2% of the metabolites were produced by endo-
phytic strains. Others have unknown origin.
The largest number of novel natural products (53) 
were produced by bacteria collected from Asia (China, 
South China Sea, Republic of Korea, Thailand, Japan 
and India), while bacteria from Australia and Oceania 
(Australia, Micronesia, Papua New Guinea and Fiji), 
North America (USA, Canada and Bahamas) and finally 
from South America (Chile) produced equally 10 new 
compounds. The other bioactive compounds derived 
from actinomycetes isolated in Africa and Europe. 
Chemical structures of the newly discovered meta-
bolites proved to be quite heterologous. Among them 
were spirotetronates, ansamycin-type compounds, 
lactones and lactams, glycosylated lactones – macro-
lides, quinones, peptides and others. Among all new 
molecules described here, the best activities displayed 
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arenimycin  C (MICs between 0.0015–0.00985 µg/ml 
against B. subtilis and MRSA), bicyclic chromopep-
tide lactone RSP 01 (MICs between 0.007–0.06 µg/ml 
against S. aureus and B. subtilis) and kocurin (MICs 
in the range of 0.008–0.512 µg/ml against S. aureus, 
E. faecium and E. faecalis). Furthermore, quite promis-
ing properties were shown for chaxamycin D (MICs 
in the range of 0.06–0.25 µg/ml against S. aureus and 
E. coli) and anthracimycin (MICs in the range of 
0.03–4.0 µg/ml against B. anthracis, E. faecalis, S. pneu­
moniae, H. influenzae, M. catarrhalis and S. aureus). 
Among the identified antifungal compounds, endus-
peptide  B, neomaclafungins A-I and kribelloside  D 
exhibited the highest activity towards fungi (MICs 1.72, 
1–3 and 3.12 µg/ml, respectively). Ahmpatinin iBu, 
antimycin A1a, and pentapeptide 4862F were found 
to be the strongest antiviral agents with IC50 values of 
15.26, < 4 and 1.79 nM, respectively.
All antibacterial, antifungal and antiviral agents pre-
sented in this review demonstrate the huge potential of 
actinomycetes as leader producers of novel bioactive 
molecules, regarded as promising candidates for clinical 
evaluation in drug development. 
The discovery, development and introduction of 
a  new antibiotic to the pharmaceutical industry are 
very laborious and complicated processes. The chemi-
cal structures of antibiotics, especially those derived 
from nature are complex. They consist of many stereo-
centers, rotatable bonds, proton donors and acceptors. 
Optimization of the molecule structure (its function 
in biological conditions), scale up of metabolites bio-
synthesis for industrial purposes as well as long time 
needed for toxicological and clinical studies makes all 
this procedures very expensive and time consuming. 
For these reasons, from an economic point of view, 
pharmaceutical companies prefer developing drugs for 
chronic diseases rather than for short-term treatments. 
One the other hand, rapidly increasing resistance of 
microorganisms makes contemporary bioactive agents 
less effective in combating different diseases or useless 
at all. It is also related with excessive and improper use 
of antibiotics in medicine, veterinary practice and agri-
culture. In this context, not to remain helpless in terms 
of bacterial infections, the discovery of new bioactive 
compounds is absolutely necessary. Both approaches, 
traditional way relying on distinct microorganisms iso-
lated from different environments, as well as innovative 
strategy using the “-omics” technologies together with 
bioinformatics, are still the valid approaches in search-
ing for novel bioactive agents. Especially, molecules 
with two modes of action and directed against novel 
targets are extremely desirable (Ziemska et al. 2013). 
Another possibilities arise from synthetic or semisyn-
thetic modifications of natural products or searching 
for novel bioactivities among previously known com-
pounds (such strategies significantly reduce research 
costs). Finally, a special attention should be placed on 
the education of the society on the wise and proper 
use of antibiotics in agriculture as well as in treatment 
of human and animal diseases.
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